Search results for "Ship"

showing 10 items of 6731 documents

Levocetirizine for the treatment of itch in psoriasis patients: An open-label pilot study in a real-world setting.

2019

Itch is the most bothersome symptom in psoriasis, often leading to impaired quality of life. Treatment of psoriasis-induced itch is frequently unsatisfactory as the various therapies employed have a delayed onset of effect. Histamine-1 receptor (H1) antihistamines are not recommended in treatment guidelines as histamine is not considered a key mediator in psoriasis. However, patients using H1 antihistamines frequently report benefits in questionnaire-based studies. To address these contradictions, we examined the short-term effects of levocetirizine, a nonsedating H1 antihistamine, on psoriasis-related itch and itch-related quality of life. In this pilot study, patients with psoriasis-relat…

AdultMalemedicine.medical_specialtyHistamine H1 Antagonists Non-SedatingTime FactorsPilot ProjectsDermatologyLevocetirizine030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineQuality of lifeimmune system diseasesPsoriasisparasitic diseasesotorhinolaryngologic diseasesMedicineEffective treatmentHumansPsoriasisskin and connective tissue diseasesH1 antihistamineDose-Response Relationship Drugbusiness.industryPruritusDelayed onsetGeneral MedicineMiddle Agedmedicine.diseaseDermatologyeye diseasesCetirizineTreatment Outcome030220 oncology & carcinogenesisConcomitantQuality of LifeFemaleOpen labelbusinessmedicine.drugDermatologic therapyREFERENCES
researchProduct

Gender-, age- and time-dependent dosing of growth hormone in adults - real-world data from a decade of clinical practice in Germany.

2017

We evaluated treatment patterns and gender-dependent dosing of growth hormone (GH) substitution in adults with GH deficiency (AGHD). Data on GH dose were collected (2003-2013) from 509 GH-treated patients (mean age: 48.9 years; 47% female) enroled in the observational German NordiWin study (NCT01543880). The impact of gender, age, treatment duration and calendar year on GH treatment patterns was evaluated by multiple regression analysis. Mean (SD) baseline GH dose (mg/day) was similar between females (0.25 [0.19] and males (0.24 [0.15]), but increased with treatment duration (at year 10, 0.55 [0.48] and 0.31 [0.09] in females and males, respectively), reflecting patient dose titration. GH d…

AdultMalemedicine.medical_specialtyHormone Replacement TherapyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPhysiology030209 endocrinology & metabolismGrowth hormoneGrowth hormone deficiency03 medical and health sciencesInsulin-like growth factor0302 clinical medicineEndocrinologySex FactorsInternal medicineGermanymedicineHumansDosingDwarfism PituitaryAgedDose-Response Relationship Drugbusiness.industryHuman Growth HormoneAge FactorsObstetrics and GynecologyMiddle Agedmedicine.diseaseClinical PracticeEndocrinologyTreatment OutcomeTransgender hormone therapy030220 oncology & carcinogenesisGh treatmentFemalebusinessReal world dataGynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
researchProduct

Blood ethanol levels and adenylyl cyclase activity in lymphocytes of alcoholic patients

1999

Abstract Background: The adenylyl cyclase (AC) signal transduction pathway is a target of acute and chronic ethanol actions. This study examined whether AC activity in lymphocyte membranes of male alcoholic patients correlated with blood concentrations of ethanol. Methods: Patients ( n = 13; mean age: 40 ± 8 years) were studied on the day of admission (day 0) and 2 days later under detoxification. Moreover, 13 age-matched male healthy controls (mean age 40 ± 9 years) were included. Lymphocyte membranes were prepared by differential centrifugation whereby blood ethanol was washed out. As a measure of AC activity the formation of cyclic adenosine monophosphate (cAMP) from adenosine triphospha…

AdultMalemedicine.medical_specialtyLymphocyteStimulationGuanosine triphosphateAdenylyl cyclasechemistry.chemical_compoundAdenosine TriphosphateInternal medicineCyclic AMPmedicineHumansCyclic adenosine monophosphateLongitudinal StudiesLymphocytesBiological PsychiatryEthanolForskolinDose-Response Relationship DrugEthanolColforsinMiddle AgedAlcoholismmedicine.anatomical_structureEndocrinologychemistryCase-Control StudiesGuanosine TriphosphatePhosphorus RadioisotopesAdenosine triphosphateAdenylyl CyclasesSignal TransductionBiological Psychiatry
researchProduct

A phase I study of oral uracil-ftorafur plus folinic acid in combination with weekly paclitaxel in patients with solid tumors.

2002

Ftorafur is an orally available prodrug of 5-fluorouracil (5-FU). Its combination with uracil in a molar ratio of 1:4 (UFT) increases the 5-FU concentration in tumor cells compared with ftorafur alone. Paclitaxel has a broad spectrum of activity against solid tumors and synergic effects with UFT have been demonstrated in vitro. A phase I study was performed to determine the maximum tolerated dose of the combination of UFT and paclitaxel in patients with advanced solid tumors.UFT and folinic acid were applied at 300 mg/m2/day and 90 mg/day, respectively, on days 1-28, repeated on day 36. Paclitaxel was applied on days 1, 8, 15 and 22 of each cycle. The starting dose of paclitaxel was 50 mg/m…

AdultMalemedicine.medical_specialtyMaximum Tolerated DosePaclitaxelmedicine.medical_treatmentLeucovorinAdministration OralPharmacologyTegafurGastroenterologyDrug Administration Schedulechemistry.chemical_compoundFolinic acidLeukocytopeniaOral administrationInternal medicineNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedTegafurChemotherapyDose-Response Relationship Drugbusiness.industryHematologyMiddle AgedSurvival AnalysisTreatment OutcomeOncologyPaclitaxelchemistryFluorouracilToxicityFemalebusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

A comparison study of moclobemide and doxepin in major depression with special reference to effects on sexual dysfunction

1993

A double-blind parallel-group comparison study of moclobemide versus doxepin in 237 patients with major depression confirmed that moclobemide was equal in efficacy and better tolerated than doxepin. It was less sedating and caused fewer anticholinergic adverse events as measured by the UKU side-effect rating scale. Unexpectedly, moclobemide therapy more often than doxepin resulted in increased sexual desire. An exploratory analysis of UKU-measured symptoms of impaired sexual function prior to commencement of the study revealed that moclobemide more often than doxepin led to an improvement of reduced libido and impaired erection, ejaculation and orgasm. This finding is compatible with the as…

AdultMalemedicine.medical_specialtyMonoamine Oxidase InhibitorsPersonality Inventorymedicine.drug_classLibidoMoclobemideSexual BehaviorDouble-Blind MethodMoclobemidemedicineAnticholinergicHumansPharmacology (medical)PsychiatryAdverse effectDepression (differential diagnoses)Depressive DisorderDose-Response Relationship DrugMiddle AgedDoxepinPsychiatry and Mental healthSexual dysfunctionAnesthesiaBenzamidesComparison studyFemaleDoxepinmedicine.symptomPsychologymedicine.drugInternational Clinical Psychopharmacology
researchProduct

Frontoparietal cortex and cerebellum contribution to the update of actual and mental motor performance during the day

2016

AbstractActual and imagined movement speed increases from early morning until mid-afternoon. Here, we investigated the neural correlates of these daily changes. Fifteen subjects performed actual and imagined right finger opposition movement sequences at 8 am and 2 pm. Both actual and imagined movements were significantly faster at 2 pm than 8 am. In the morning, actual movements significantly activated the left primary somatosensory and motor areas, and bilaterally the cerebellum; in the afternoon activations were similar but reduced. Contrast analysis revealed greater activity in the cerebellum, the left primary sensorimotor cortex and parietal lobe in the morning than in the afternoon. Im…

AdultMalemedicine.medical_specialtyMovementMuscle memoryAudiology050105 experimental psychologyFunctional LateralityArticlepositron-emission-tomographyFingers03 medical and health sciencesYoung Adult0302 clinical medicineCortex (anatomy)CerebellumParietal LobemedicineHumans0501 psychology and cognitive sciencesfunctional mritimeMorningBrain MappingMultidisciplinarybusiness.industryhand movements05 social sciencesParietal lobeMotor Cortexrepresentationscircadian-rhythm periodMotor coordinationFrontal Lobemedicine.anatomical_structureFrontal lobeparietal cortexbody ownership[ SDV.NEU ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Imaginationfinger movementsOrbitofrontal cortexFemaleArtificial intelligenceMotor learningbusiness030217 neurology & neurosurgeryPsychomotor Performanceimagery
researchProduct

Relaxation by β3-adrenoceptor agonists of the isolated human internal anal sphincter

2009

In this study, responses of beta(3)-adrenoceptor agonists were examined on human isolated internal anal sphincter (IAS) in order to explore their relaxant effects on hypertonicity of IAS.The relaxant efficacy (E(max)) and potency (-logIC(50)) of BRL37344 and SR58611A, beta(3)-adrenoceptor agonists, were examined in contracted IAS muscle strips. The presence of beta(3)-adrenoceptors, and changes in intracellular calcium and cyclic nucleotide levels in IAS muscle were tested by Western blotting, epifluorescence microscopy and enzyme immunoassay, respectively.BRL37344 and SR58611A relaxed contracted IAS muscle (E(max)=27+/-3% and 35+/-3%; -logIC(50)=6.26+/-0.24 and 4.87+/-0.13; respectively). …

AdultMalemedicine.medical_specialtyMuscle RelaxationAnal CanalAdrenergic beta-3 Receptor AgonistsIn Vitro TechniquesGeneral Biochemistry Genetics and Molecular BiologyCalcium in biologyInternal anal sphincterInternal medicinemedicineHumansPotencyGeneral Pharmacology Toxicology and PharmaceuticsAgedAged 80 and overDose-Response Relationship DrugRelaxation (psychology)Sphincter tonebusiness.industryGeneral MedicineAdrenergic beta-AgonistsMiddle AgedEndocrinologyEthanolaminesReceptors Adrenergic beta-3Femaleβ3 adrenoceptorbusinessLife Sciences
researchProduct

Is there a relationship between chocolate consumption and symptoms of depression? A cross-sectional survey of 13,626 US adults

2019

Objective: To examine associations between chocolate consumption and depressive symptoms in a large, representative sample of US adults. Methods: The data were from 13,626 adults (≥20 years) participating in the National Health and Nutrition Examination Survey between 2007–08 and 2013–14. Daily chocolate consumption was derived from two 24-hr dietary recalls. Depressive symptoms were assessed using the Patient Health Questionnaire (PHQ-9), with scores ≥10 indicating the presence of clinically relevant symptoms. We used multivariable logistic regression to test associations of chocolate consumption (no chocolate, non-dark chocolate, dark chocolate) and amount of chocolate consumption (grams/…

AdultMalemedicine.medical_specialtyNational Health and Nutrition Examination SurveyCross-sectional studyPopulationDark chocolatePatient Health QuestionnaireLogistic regressionDiet SurveysYoung AdultfoodEnvironmental healthEpidemiologymedicineHumansChocolateeducationLife StyleAgedAged 80 and overeducation.field_of_studybusiness.industryDepressionchocolate dark chocolate depressive symptoms epidemiology NHANESNHANES chocolate dark chocolate depressive symptoms epidemiologyMiddle Agedfood.foodUnited StatesPatient Health QuestionnairePsychiatry and Mental healthClinical PsychologyCross-Sectional StudiesLogistic ModelsQuartileJackson S. Smith L. Firth J. Grabovac I. Soysal P. Koyanagi A. Hu L. Stubbs B. Demurtas J. Veronese N. et al. -Is there a relationship between chocolate consumption and symptoms of depression? A cross-sectional survey of 13626 US adults.- Depression and anxiety cilt.36 ss.987-995 2019Femalebusiness
researchProduct

Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma

2000

The efficacy of oxaliplatin combined with high-dose 5-fluorouracil (5-FU) and folinic acid (FA) as an outpatient salvage treatment for patients with metastasized colorectal cancer was retrospectively analyzed in one center. Tumor progression had occurred for the majority of patients during two regimens (n = 11) otherwise during one (n = 1) regimen of prior 5-FU-based chemotherapy, which had been applied in a standardized sequential fashion. As third-line therapy oxaliplatin was infused intravenously over 2 h at a dose of 60 mg/m2 prior to a 2-h infusion of FA (500 mg/m2). 5-FU (2,600 mg/m2) was subsequently given over 24 h. A favorable response was observed in 9/12 (75%) of the heavily pret…

AdultMalemedicine.medical_specialtyOrganoplatinum CompoundsNauseaColorectal cancermedicine.medical_treatmentLeucovorinGastroenterologyDisease-Free SurvivalDrug Administration ScheduleFolinic acidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineInfusions IntravenousAgedNeoplasm StagingRetrospective StudiesSalvage TherapyChemotherapyDose-Response Relationship Drugbusiness.industryPalliative CareGastroenterologyMiddle Agedmedicine.diseaseOxaliplatinOxaliplatinRegimenFluorouracilColon neoplasmFemaleFluorouracilmedicine.symptomColorectal Neoplasmsbusinessmedicine.drugZeitschrift für Gastroenterologie
researchProduct

Influenza vaccination coverage among medical residents: An Italian multicenter survey

2014

Although influenza vaccination is recognized to be safe and effective, recent studies have confirmed that immunization coverage among health care workers remain generally low, especially among medical residents (MRs). Aim of the present multicenter study was to investigate attitudes and determinants associated with acceptance of influenza vaccination among Italian MRs. A survey was performed in 2012 on MRs attending post-graduate schools of 18 Italian Universities. Each participant was interviewed via an anonymous, self-administered, web-based questionnaire including questions on attitudes regarding influenza vaccination. A total of 2506 MRs were recruited in the survey and 299 (11.9%) of t…

AdultMalemedicine.medical_specialtyPediatricsAttitude of Health PersonnelImmunologySocio-culturaleSettore MED/42 - Igiene Generale E ApplicataInfluenza immunizationmedical residentsPhysiciansHealth careInfluenza Humanmedicineinfluenza vaccination; coverage rateImmunology and AllergyHumansGood practiceCoverage rate; Influenza vaccination; Italy; Medical residents; Multicentre survey; Adult; Female; Humans; Influenza Vaccines; Influenza Human; Italy; Male; Vaccination; Attitude of Health Personnel; Data Collection; Internship and Residency; Physiciansmulticentre surveyEthical responsibilityPharmacologyCoverage rate; Influenza vaccination; Italy; Medical residents; Multicentre surveybusiness.industryinfluenza vaccination; medical residents; multicentre survey; coverage rate; ItalyData CollectionVaccinationInternship and ResidencyItaly coverage rate influenza vaccination medical residents multicentre surveyInfluenzainfluenza vaccinationVaccinationMulticenter studyItalyInfluenza VaccinesVaccination coverageFamily medicineCoverage rate; Influenza vaccination; Italy; Medical residents; Multicentre survey; Immunology and Allergy; Immunology; PharmacologyMulticenter surveyFemalebusinesscoverage rateResearch PaperHuman
researchProduct